1. Home
  2. NRIM vs ALT Comparison

NRIM vs ALT Comparison

Compare NRIM & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NRIM

Northrim BanCorp Inc

HOLD

Current Price

$25.83

Market Cap

602.6M

Sector

Finance

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$3.27

Market Cap

573.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRIM
ALT
Founded
1990
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
602.6M
573.8M
IPO Year
2002
2005

Fundamental Metrics

Financial Performance
Metric
NRIM
ALT
Price
$25.83
$3.27
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$17.67
AVG Volume (30 Days)
99.4K
4.2M
Earning Date
04-22-2026
05-08-2026
Dividend Yield
2.62%
N/A
EPS Growth
N/A
25.37
EPS
1.29
N/A
Revenue
$255,581,000.00
$41,000.00
Revenue This Year
$4.98
N/A
Revenue Next Year
$7.40
N/A
P/E Ratio
$19.67
N/A
Revenue Growth
30.43
105.00
52 Week Low
$19.60
$2.56
52 Week High
$93.80
$6.44

Technical Indicators

Market Signals
Indicator
NRIM
ALT
Relative Strength Index (RSI) 36.92 54.47
Support Level $24.78 $2.80
Resistance Level $25.47 $3.32
Average True Range (ATR) 0.59 0.12
MACD -0.08 0.00
Stochastic Oscillator 15.82 69.23

Price Performance

Historical Comparison
NRIM
ALT

About NRIM Northrim BanCorp Inc

Northrim BanCorp Inc is a bank holding company operating through three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. The Community Banking segment, which generates the majority of revenue, provides loan and deposit products to business and consumer customers in its market areas. The Home Mortgage Lending segment focuses on the origination and sale of mortgage loans for one-to-four family residential properties, mortgage loan servicing for certain loans sold, and investment in selected residential mortgage loans. The Specialty Finance segment provides factoring, asset-based lending, and alternative working capital solutions to small and medium-sized enterprises and includes SCF and Northrim Funding Services.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: